Emphysema Clinical Trial
— RENEWOfficial title:
Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study
NCT number | NCT01608490 |
Other study ID # | CLN0009 |
Secondary ID | |
Status | Terminated |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2012 |
Est. completion date | July 26, 2019 |
Verified date | July 2021 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Status | Terminated |
Enrollment | 315 |
Est. completion date | July 26, 2019 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years and older |
Eligibility | Inclusion Criteria: - Subject is greater than or equal to 35 yrs of age - CT Scan indicates bilateral emphysema, as determined by the Core Radiology Lab using the criteria presented in the "CT Scoring Plan for Core Radiology Lab" - Subject has post-bronchodilator FEV1 less than or equal to 45% predicted - Subject has Total Lung Capacity >100% predicted - Subject has residual volume (RV) greater than or equal to 175% predicted - Subject has marked dyspnea greater than or equal to 2 on mMRC scale of 0-4 - Subject has stopped smoking for at least 8 weeks prior to entering the study as confirmed by a Cotinine test or other appropriate diagnostic test. - Subject has completed a pulmonary rehabilitation program within 6 mos prior to treatment and/or is regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 mos prior to baseline testing. - Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy. - Subject (and legal guardian, if applicable) has read, understood, and signed the Informed Consent form. Exclusion Criteria: - Subject has severe homogeneous emphysema determined by Core Radiology Lab. - Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea. - Subject has a change in FEV1 of greater than 20% (or, for subjects with pre-bronchodilator FEV1 below 1L, a change of greater than 200mL) post-bronchodilator unless investigator can confirm by other means that subject does not have asthma. - Subject has DLCO of less than 20% of predicted. - Subject has severe gas exchange abnormalities, PaCO2 of greater than 55mm Hg; PaO2 of less than 45 mm Hg on room air (high altitude criterion: PaO2 of less than 30mm Hg). - Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment. - Subject as severe pulmonary hypertension defined by right ventricular systolic pressure of greater than 50mm Hg via right heart catheterization and/or echocardiogram - Subject has an inability to walk >140m (150 yd) in 6 minutes - Subject has evidence of other severe disease (such as but not limited to lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study. - Subject is pregnant or lactating, or plans to become pregnant within the study timeframe. - Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia. - Subject has clinically significant bronchiectasis. - Subject has giant bullae >1/3 lung volume - Subject has had previous LVR surgery, lung transplantation, lobectomy or LVR devices or other device to treat COPD in either lung. - Subject has been involved in pulmonary drug or device studies within 30 days prior to this study. - Subject is taking >20mg prednisone (or equivalent dose of a similar steroid) daily. - Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder. - Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as Heparin or Coumadin) which cannot be stopped for 7 days prior to the procedure. - Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes. - Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals. - Subject has a known sensitivity to drugs required to perform bronchoscopy. - Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD). |
Country | Name | City | State |
---|---|---|---|
Canada | Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) | Quebec | |
France | Centre Hospitalier Universitaire de Nice | Nice | |
France | CHU de Reims - Hopital Maison Blanche | Reims | |
Germany | Thoraxklinik University of Heidelberg | Heidelberg | |
Netherlands | University Medical Center Groningen | Groningen | |
United Kingdom | Royal Brompton Hospital & Chelsea Westminster | London | |
United States | University of Michigan Health System | Ann Arbor | Michigan |
United States | Pulmonary and Critical Care Associates of Baltimore | Baltimore | Maryland |
United States | University of Alabama Lung Health Center | Birmingham | Alabama |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Northwestern University | Chicago | Illinois |
United States | University of Illinois Hospital and Health Center | Chicago | Illinois |
United States | The Cleveland Clinic | Cleveland | Ohio |
United States | National Jewish Health | Denver | Colorado |
United States | Duke University Medical Center | Durham | North Carolina |
United States | University of Florida | Gainesville | Florida |
United States | Pulmonary, Critical Care & Sleep Medicine Consultants,PCCS/St. Luke's Episcopal Hospital | Houston | Texas |
United States | Cedars Sinai Medical Center | Los Angeles | California |
United States | University of Wisconsin School of Medicine & Public Health | Madison | Wisconsin |
United States | El Camino Hospital/Palo Alto Medical Foundation | Mountain View | California |
United States | Yale University School of Medicine - Yale New Haven Hospital | New Haven | Connecticut |
United States | New York Presbyterian Columbia University Medical Center | New York | New York |
United States | Illinois Lung and Critical Care Institute | Peoria | Illinois |
United States | Temple | Philadelphia | Pennsylvania |
United States | Emphysema COPD Research Center, University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Mayo Clinic | Rochester | Minnesota |
United States | University of Texas Health Sciences Center at San Antonio | San Antonio | Texas |
United States | Franciscan Research Center | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation | PneumRx, Inc. |
United States, Canada, France, Germany, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | SGRQ Responder Analysis | SGRQ Responder Analysis: Responder defined as those with an improvement greater than or equal to 4 points | 12 months | |
Other | Residual Volume (RV) Mean Absolute Difference in RV From Baseline to 12 Months | Mean absolute difference in RV results measured using plethysmography, comparing BL to 12 months, LVRC vs. Control | 12 months | |
Other | RV/TLC Mean Absolute Difference From Baseline to 12 Months | Mean absolute difference in RV/TLC (residual volume/total lung capacity - a measure done during lung function testing where residual volume is air left over in lung after completely breathing out and total lung capacity is how much air the lung can breathe in) results measured using plethysmography, comparing BL to 12 months, LVRC vs. Control | 12 months | |
Primary | Meters: 6 Minute Walk Test - Change From Baseline to 12 Months Follow up | mean absolute change from baseline at 12 months in the 6 Minute Walk Test comparing test and control groups (median if skewed) | baseline through 12 months follow up | |
Secondary | Mean Percent Change in FEV1 From Baseline to 12 Months | Mean percent change in FEV1(Forced Expiratory Volume in 1 second) at 12 months (median if skewed) | BL to 12 months | |
Secondary | St. George's Respiratory Questionnaire (SGRQ) Mean Absolute Change From Baseline to 12 Months | mean absolute difference in SGRQ results comparing BL to 12 months, LVRC vs. Control, score is on a scale from 0 to 100, negative change will be a better outcome. | BL to 12 months | |
Secondary | 6MWT Responder Analysis | 6MWT Responder Analysis: Responder is defined as those with an improvement of greater than or equal to 25 meters | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Completed |
NCT02914340 -
REACH SVS Control Patient Cross-Over Study
|
N/A | |
Completed |
NCT02999685 -
Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT02238327 -
Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01710449 -
Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
|
Phase 1 | |
Completed |
NCT00475007 -
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
|
N/A | |
Suspended |
NCT00523094 -
Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Completed |
NCT00000621 -
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)
|
Phase 2 | |
Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
Recruiting |
NCT04537182 -
Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema
|
N/A | |
Active, not recruiting |
NCT02713347 -
Advancing Symptom Alleviation With Palliative Treatment
|
N/A | |
Recruiting |
NCT04302272 -
STRIVE Post-Market Registry Study
|
||
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Completed |
NCT03636347 -
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
|
Phase 2 |